Combination Antibody Market by 2024
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
Report Media Releases<br />
<strong>Combination</strong> <strong>Antibody</strong> <strong>Market</strong> in APAC Region Set to Witness<br />
Robust Growth through <strong>2024</strong><br />
Higher success ratio in treating and preventing cancer cells using combination antibody therapy<br />
is fuelling the demand for combination antibody drugs in the market. A study conducted <strong>by</strong><br />
Persistence <strong>Market</strong> Research (PMR) shows that the global market for combination antibody<br />
therapy is set to ride on a value CAGR of over 14% during the period of assessment to reach<br />
US$ 144,734.5 Million <strong>by</strong> <strong>2024</strong> end. In 2016, the global market was valued at over US$ 49,994<br />
Million characterizing the overwhelming popularity of antibody/antibody drugs amongst both<br />
practitioners and patients observed in recent years.<br />
<strong>Combination</strong> antibody therapy is receiving higher recognition from the oncological branch of<br />
medical science research. This is primarily due to the growing use of combination therapy over<br />
single drug treatments such as radiation or chemotherapy. In addition, companies that<br />
manufacture combination antibody drugs are actively focusing on developing superior drugs that<br />
will deliver standout results. Factors such as encouraging government policies, growing<br />
concerns over higher cancer prevalence worldwide, and increasing research and development<br />
activities coupled with heavier investments are expected to boost the overall market growth in<br />
the near future. Likewise, healthy R&D pipelines are leading towards higher product offerings<br />
and also propelling the growth of global combination antibody therapy market to a<br />
significant extent.<br />
A Sample of this Report is Available Upon Request @<br />
http://www.persistencemarketresearch.com/samples/11740<br />
Bottlenecks<br />
The prolonged attrition rate in product development cycle and arbitrary and stringent drug<br />
approval procedures are the major downsides of the market that are likely to inhibit the market<br />
growth during the forecast period. Moreover, lack of awareness on understanding the difference<br />
between immunotherapies and chemotherapies amongst healthcare professionals, which is<br />
restricting the optimal use of immunotherapies alongside conventional treatment modalities is an<br />
additional factor impeding the market growth. Further, late diagnosis or ignorance of any<br />
carcinogenic disorders may inevitably lead to higher cost of treatment.<br />
<strong>Market</strong> Forecast<br />
Based on combinations, antibody/antibody is projected to be the predominant segment of the<br />
market over the forecast period. In terms of revenue, the segment is expected to witness a<br />
healthy CAGR of over 17% between 2016 and <strong>2024</strong>. The growth is attributed to the increasing<br />
preference of antibody/antibody drugs as they have a lower risk of side effects for various cancer<br />
therapies. Whereas, the chemotherapy/antibody segment will hold the second position,<br />
accounting for 38.3% share of the market in 2016.<br />
<strong>Combination</strong> <strong>Antibody</strong> Therapy <strong>Market</strong> <strong>2024</strong>
Change language